You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
最新醫學分析:禮來減肥藥Mounjaro較諾和諾德Ozempic更有效
阿思達克 11-28 01:22
根據周一最新發布的臨床試驗大型分析,對於超重或肥胖的成年人而言,禮來(LLY.US)重磅糖尿病藥物Mounjaro較諾和諾德廣受歡迎的治療藥物Ozempic更有效。 Truveta Research專門檢查約18,000名超重或肥胖成年人的醫療保健數據,在2022年5月至2023年9月期間首次開始服用Mounjaro或Ozempic。其中近52%的患者患有2型糖尿病,結果發現,服用禮來藥物的患者與諾和諾德的參與者相比,Mounjaro試用者整體體重減輕5%、10%和15%的可能性明顯更大,並且在三個月、六個月和一年後體重減輕幅度更大。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account